What is Abcodia?
Abcodia is a pioneering healthtech enterprise focused on the development and commercialization of advanced diagnostic tests for ovarian cancer. Its core offering, the ROCA Test, provides a critical surveillance mechanism for women over 35 who carry BRCA1 or BRCA2 gene mutations. By assessing risk profiles through blood-based biomarkers, the company offers a vital alternative for patients seeking to manage their genetic predisposition while delaying invasive preventative surgeries. Currently integrated into specific NHS pathways and private clinical networks, Abcodia serves as a bridge between academic research and practical clinical application, addressing a significant unmet need in women's health and preventative oncology.
How much funding has Abcodia raised?
Abcodia has raised a total of $8.2M across 1 funding round:
Unspecified
$8.2M
Unspecified (2015): $8.2M with participation from Cambridge Innovation Capital, UCL Business PLC, Albion Ventures, and Scottish Equity Partners
Key Investors in Abcodia
Cambridge Innovation Capital
Cambridge Innovation Capital is a venture capital investor focused on intellectual property rich technology and life science businesses in the Cambridge ecosystem.
UCL Business PLC
UCLB is the commercialisation company of University College London, dedicated to bringing world-leading technologies and innovations to market.
Albion Ventures
AlbionVC is the technology investment arm of Albion Capital Group LLP, managing approximately 1 billion in venture funds and supporting visionary founders with long-term capital and scale-up expertise.
What's next for Abcodia?
Looking ahead, Abcodia is poised to leverage its recent capital infusion to scale its operational footprint and deepen its integration within the healthcare ecosystem. The strategic focus will likely center on expanding the clinical adoption of the ROCA Test, potentially moving beyond current regional limitations to broader national and international markets. As the company transitions into a more mature growth phase, the emphasis will remain on rigorous clinical validation and the cultivation of strategic partnerships with healthcare providers. By maintaining its commitment to high-quality diagnostic surveillance, Abcodia is set to play a pivotal role in the future of personalized cancer risk management, ensuring that high-risk patients receive timely and actionable insights.
See full Abcodia company page
